A renaissance in therapeutic options for pancreatic neuroendocrine tumors. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Kunz, P. L. 2012: 271-274


The field of pancreatic neuroendocrine tumors (NETs) has seen a remarkable renaissance in recent years with exponential increases in published research, clinical trials, and U.S. Food and Drug Administration (FDA)-approved treatments. Surgical resection remains the foundation for management of locoregional disease. However, for patients with advanced disease, novel therapeutic options have emerged. Two separate randomized placebo-controlled studies have shown prolonged progression-free survival (PFS) with everolimus or sunitinib. Future studies are designed to answer questions about the role of somatostatin analogs as antiproliferative agents, combinations of biologic therapies, and new cytotoxic chemotherapy backbones.

View details for DOI 10.14694/EdBook_AM.2012.32.271

View details for PubMedID 24451747